Incoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday night:

Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares $KBIO

— Martin Shkreli (@MartinShkreli) November 20, 2015

So happy to rescue $KBIO from having to discontinue our promising blood cancer drug lenzilumab. Let's hire the downsized employees back too!

— Martin Shkreli (@MartinShkreli) November 20, 2015

Insiders' Blog Management Comments

KaloBios Pharma (KBIO) Receives NASDAQ Delisting NoticeNovember 23, 2015 5:46 PM Macrocure (MCUR) Ramps HigherNovember 20, 2015 10:47 AM KaloBios Pharma (KBIO) Names Martin Shkreli as CEONovember 20, 2015 6:16 AM KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New FinancingNovember 19, 2015 11:33 PM Needham & Company Drops Coverage of KaloBios Pharma (KBIO) November 19, 2015 4:42 PM